Latest Asx Filings News

Woolworths Group Limited has updated its dividend details, confirming a fully franked 45 cent per share payout for the first half of FY25 and setting the Dividend Reinvestment Plan price at $27.78.

Peak Rare Earths has secured court approval for its acquisition by Shenghe Resources, marking a pivotal moment with shares set to suspend and delist soon. Shareholders will receive $0.443 per share as the scheme moves toward completion.

The Supreme Court of New South Wales has approved Shenghe Resources’ acquisition scheme for Peak Rare Earths, setting the stage for a significant ownership change and share suspension on the ASX.

Kogan.com Ltd has announced a fully franked ordinary dividend of 7 cents per share for the six months ending June 2025, alongside details of its Dividend Reinvestment Plan pricing.

An application to the Takeovers Panel challenges Duxton Farms’ recent merger and share placement, alleging undisclosed associations and potential breaches of takeover laws by major shareholders.

Elanor Investors Group is set to reclaim over 12 million stapled securities from Challenger’s Fidante subsidiary as part of unwinding their strategic partnership, reshaping ownership stakes and signaling a new chapter for the funds manager.

Wellnex Life Limited has expanded its financing with a new A$2.5 million loan facility, enhancing its financial flexibility to support ongoing business growth and settle long-term obligations.

Altitude Minerals has successfully raised $2.5 million to advance exploration at its promising silver and gold projects in Nevada and copper-gold targets in New South Wales, aiming to sustain momentum through 2026.

Lunnon Metals has formalized an Ore Purchase Agreement with Gold Fields subsidiary St Ives Gold Mining, setting the stage for development of the high-grade Lady Herial gold deposit. The agreement outlines a 70, 30 free cash flow split and awaits shareholder and regulatory approvals.

InVert Graphite has appointed Andrew Lawson as Managing Director following his initial CEO tenure, signaling confidence in his leadership as the company advances its critical minerals projects.

CLINUVEL Pharmaceuticals has presented compelling new case studies demonstrating the efficacy of SCENESSE® in treating vitiligo, showing significant and stable repigmentation in patients. These findings, shared at the EADV conference, hint at a potential breakthrough for a condition with limited treatment options.

Atlas Arteria has announced an ordinary dividend of AUD 0.20 per security for the six months ending June 2025, payable in early October. The dividend is fully unfranked, reflecting the company’s international income streams.